

## IPSOGEN Strengthens its Patent Position with U.S. Allowance of Additional JAK2 V617F Claims

**MARSEILLE, France August 30, 2010** - **IPSOGEN** (Alternext - FR0010626028 - ALIPS) announced today that the United States Patent and Trademark Office (USPTO) has allowed claims that strengthen the company's patent position for the detection and diagnostic use of the JAK2 V617F mutation.

The newly granted U.S. Patent No. 7,781,199 builds upon the claims of the earlier patent, U.S. Patent No. 7,429,456, granted on September 30, 2008, which covered the determination of the JAK2 V617F mutation in patient samples as an indicator of myeloproliferative neoplasms. The new patent significantly expands IPSOGEN's patent protection related to the JAK2 V617F mutation to include:

- Isolated variant proteins, isolated nucleic acid sequences, specific primer and probe sets,
- Kits for the detection of the mutation.
- Isolated siRNA sequences to reduce expression of variant JAK2 protein in isolated cell system,
- Recombinant mammalian cells expressing the isolated variant of human JAK2 protein

Both 7,781,199 and 7,429,456 patents are exclusively licensed to IPSOGEN.

"The allowance of expanded claims for our JAK2 V617F mutation technology by the USPTO reinforces IPSOGEN's strong Intellectual Property position, particularly with our exclusive rights to the JAK2 patent portfolio. This recent decision of the USPTO to allow further claims related to the JAK2 V617F mutation will help sustain our efforts to allow a broad use of the JAK2 V617F in the US territory through a combination of strategic licensing agreements and product sales to leading cancer institutions, hospitals, and commercial labs" said Vincent Fert, CEO of IPSOGEN.

**About Myeloproliferative Neoplasms and JAK2 mutation.** Testing for the JAK2 V617F mutation is recommended in the World Health Organization's 2008 guidelines as an aid in the diagnosis of patients suspected of having a BCR-ABL negative myeloproliferative neoplasm (MNP). This group of neoplasms, all chronic, is characterized by an overproduction of some blood cell types by the bone marrow. The three main BCR-ABL negative myeloproliferative neoplasms are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). MPN prevalence is approximately 45-50 cases / 100,000. There is currently no definitive treatment for MPN; a wide range of supportive or modulating treatments are available based on disease severity, from phlebotomy to anti-agregants to chemotherapy.

### About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patient and oncologist decisions along their complex therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with cancer, Ipsogen is committed to the development and promotion of molecular diagnostic standards that have a significant impact on patients, medical professionals and society. As of 31 December 2009, Ipsogen has 65 employees and is located in Marseille, France. Its North American subsidiary, IPSOGEN Inc, is in Stamford, CT, USA.

### Forward-looking statements

This press release contains “forward-looking statements” as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. IPSOGEN SA does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of IPSOGEN SA, among others, the extent to which IPSOGEN’s technology platform can be used in biomarker analysis, uncertainty of market acceptance of IPSOGEN’s technologies or ability to compete against existing technologies.

### Contacts



#### **IPSOGEN**

##### **Vincent Fert**

CEO

Tel: + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

##### **Pascale Boissel**

CFO

Tel: + 33 (0)4 9129 3090

[pascale.boissel@ipsogen.com](mailto:pascale.boissel@ipsogen.com)

#### **NewCap.**

##### **Financial communication and investor relations**

Axelle Vuillermet

& Pierre Laurent

Tel: + 33 (0)1 4471 9493

[ipsogen@newcap.fr](mailto:ipsogen@newcap.fr)